Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2021.723038
Abstract: RPH-120 is a novel fully human anti-PD-L1 IgG1 monoclonal antibody with specifically designed Asn300Ala mutation in Fc fragment. Surface plasmon resonance assay showed that affinity of the RPH-120 to the dimeric form of human PD-L1-Fc… read more here.
Keywords: novel; rph 120; preclinical characterization; anti ... See more keywords